- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01329406
Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis
A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis
The present study will aim to evaluate the efficacy of milnacipran in the treatment of pain due to osteoarthritis (OA), that is, to determine whether milnacipran provides superior efficacy to placebo in patients with OA. Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is currently approved in the United States in the treatment of major depressive disorder and fibromyalgia. There is increased evidence to suggest that SNRIs may be effective in the treatment of chronic pain conditions, such as OA.
The hypothesis in this study is that the survival time (time from randomization to loss of efficacy) of milnacipran group is superior to that of placebo group.
Study Overview
Detailed Description
The study design is a Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study. This means that, upon entry into the study, all subjects will enter an open-label period during which they will take milnacipran for 4 weeks. Subjects will taper their dose up to one 100mg tablet twice daily for a total of 200mg per day. After 4 weeks, the subject will return to the clinic and be re-evaluated.
Only subjects who meet certain criteria are then randomized to continue in the double-blind period of the study. Once a subject is randomized, he or she will take either milnacipran or placebo for another 4 weeks. Following the double-blind period, subjects will be tapered off the study medication and will receive a phone call once each week for 2 weeks for follow-up assessments.
Throughout the study, subjects will complete various questionnaires and other test procedures aimed at sub-typing subjects based on pain mechanisms.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Natick, Massachusetts, United States, 01760
- Recruiting
- Analgesic Solutions
-
Contact:
- Karen Cowles, RN, MPH
- Phone Number: 121 781-444-9605
- Email: kcowles@analgesicsolutions.com
-
Contact:
- Courtney Lincoln
- Phone Number: 119 781-444-9605
- Email: clincoln@analgesicsolutions.com
-
Principal Investigator:
- Stephen L. Wright, M.D.
-
Sub-Investigator:
- Nathaniel P. Katz, M.D., M.S.
-
Sub-Investigator:
- Eric Osgood, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be 21-75 years of age and in good general medical and psychological health
- Be able to speak, read, write, and understand English, understand the consent form, complete study related procedures, and communicate with the study staff
- Have a negative urine pregnancy test at screening, and use appropriate birth control
Have documented painful Osteoarthritis (OA) of at least one knee for at least 6 months; OA should be of Class I-III and meet the American College of Rheumatology (ACR) clinical classification criteria, defined as:
Knee pain and at least 3 of the following 6:
- Age > 50
- Morning stiffness < 30 minutes
- Crepitus on active motion
- Bony tenderness
- Bony enlargement
- No palpable warmth of synovium
- The target joint must not contain any type of orthopedic and/or prosthetic device
- Have a target joint pain average of 5 days per week and have an average pain intensity of at least 4/10 on the 0-10 NRS over the last 24 hours prior to screening
- Have stable treatment modalities, e.g. acupuncture, physical therapy
- Be willing to stop taking Non-steroidal Anti-inflammatory drugs (NSAIDs) and opioids for the duration of the study
Exclusion Criteria:
- Are allergic or intolerant to SNRI; have a previous poor response to a SNRI for OA pain; are currently taking an SNRI or tricyclic antidepressant
- Have a body mass index (BMI) >40 kg/m2
- Have an Hospital Anxiety and Depression Scale (HADS) score >12 on either subscale or has an established history of major depressive disorder not controlled with medication
- Have significant pain outside the target knee, including significant hip or back pain. (Bilateral knee OA allowed.)
- Have pain affecting the target knee that is due to any other etiology than OA
- Have documented history of inflammatory arthritis including rheumatoid arthritis
- Have had local injections in target joint within the past 3 months prior to screening
- Have had oral or intramuscular corticosteroids within the past 30 days
- Have had worker's compensation claim, disability, or litigation
- Have a known history of uncontrolled narrow-angle glaucoma
- Have a known history of suicidal ideation
- Use monoamine oxidase inhibitors (MAOI) concomitantly
- Are allergic or intolerant to acetaminophen
- Using opioids 4 or more days per week during the month preceding the screening visit
- Have significant history or renal impairment/failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Milnacipran
If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks.
The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).
|
1 tablet (100mg) by mouth twice daily for 28 days
|
Placebo Comparator: Placebo
If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks.
The placebo group will take 1 tablet twice daily.
|
1 tablet by mouth twice daily for 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to loss of efficacy in the Double-Blind Period
Time Frame: 28 days
|
The time to pain worsening by 30% compared to the value at baseline and a pain score of at least 4 on the 0-10 numerical rating scale on weekly pain assessment.
Subjects who drop out due to "lack of efficacy" will be counted as efficacy failures regardless of their pain scores.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in pain intensity
Time Frame: 28 days
|
Mean change in pain intensity on the 0-10 numerical rating scale from baseline in the Double-Blind Period.
|
28 days
|
Mean change in Western Ontario and McMaster Osteoarthritis Index (WOMAC) scores
Time Frame: 28 days
|
Mean change in Western Ontario and McMaster Osteoarthritis Index (WOMAC) scores from Baseline in the Open-Label Period and Double-Blind Period.
|
28 days
|
The efficacy of milnacipran vs. placebo by time to dropout for all causes
Time Frame: 70 days
|
70 days
|
|
The efficacy of milnacipran in the Open-Label Period
Time Frame: 28 days
|
The efficacy of milnacipran in the Open-Label Period defined by the change in pain intensity from Baseline to the end of the period and responder proportion.
|
28 days
|
The difference between milnacipran and placebo in responder proportion in the Double-Blind Period
Time Frame: 28 days
|
28 days
|
|
The predictive value of "OA sensory sub-type" for predicting the response to milnacipran vs. placebo
Time Frame: 70 days
|
70 days
|
|
Safety and tolerability by monitoring adverse events
Time Frame: 70 days
|
70 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen L. Wright, M.D., Analgesic Solutions
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Milnacipran
- Levomilnacipran
Other Study ID Numbers
- FRX001-2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Mayo ClinicCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Sword Health, SAHospital da PreladaCompletedEfficacy of a Digital Biofeedback System for Home-based Rehabilitation After Total Joint ReplacementKnee Osteoarthritis | Hip OsteoarthritisPortugal
-
The Hawkins FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Massachusetts General HospitalNewton-Wellesley HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Milnacipran
-
Indiana UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
Pierre Fabre MedicamentCompletedFibromyalgia SyndromeSpain, Italy, Portugal, France, Czech Republic, Finland, Germany, Norway, Romania, Sweden, Denmark, Poland, United Kingdom
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
Chang Gung Memorial HospitalUnknownDepression | Ischemic StrokeTaiwan
-
California Medical Clinic for HeadacheUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraUnited States
-
Forest LaboratoriesCompleted
-
Pierre Fabre MedicamentCompletedFibromyalgia SyndromeSpain, Italy, Portugal, France, Czech Republic, Finland, Germany, Norway, Romania, Sweden
-
Valera BussellForest LaboratoriesCompleted
-
Forest LaboratoriesCypress Bioscience, Inc.Completed
-
Dr. Norman HardenForest LaboratoriesCompletedChronic Pain | Knee Osteoarthritis | Degenerative Joint Disease